不同全球区域患者碳青霉烯类耐药鲍曼不动杆菌的临床结局与细菌特征
这项前瞻性观察性队列研究纳入2017至2019年全球五个区域46家医院的842例住院患者,其中536例(64%)为感染。感染患者30天全因死亡率为24%(128/536),不同区域差异显著;菌血症患者死亡率高于其他感染类型(42% vs 20%)。CG2克隆群菌株占主导,但非CG2菌株与更高死亡率相关。
要点
- 菌血症患者死亡风险高于其他感染类型(40/96 vs 88/440),多变量分析中血流感染与30天死亡率独立相关。
- CG2菌株占主导但非CG2菌株在死亡病例中占比更高,且CG2与更高美罗培南耐药水平显著相关。
核心结论
- CRAb感染类型和临床结局在不同区域间存在显著差异。
- 尽管CG2菌株仍占主导,但非CG2菌株与更高死亡率相关。
研究设计与样本
- 前瞻性观察性队列研究,纳入2017至2019年全球五个区域46家医院的842例临床CRAb培养阳性住院患者,菌株行全基因组分析。
- 主要结局为自指标培养起30天全因死亡率。
主要发现
- 842例中536例(64%)为感染;感染患者30天死亡128例(24%),区域范围从澳大利亚-新加坡18例中1例(6%)至美国216例中54例(25%)及中南美洲49例中24例(49%);非感染患者死亡42例(14%)。
- 菌血症与其他感染类型相比死亡风险更高(96例中40例[42%] vs 440例中88例[20%])。
- 多变量logistic回归分析中,血流感染和较高年龄校正Charlson合并症指数与30天死亡率独立相关。
- CG2菌株除中南美洲外占主导,范围从美国369株中216株(59%)至中国291株中282株(97%);842株中769株(91%)携带获得性碳青霉烯酶基因。
- CG2菌株与更高水平的美罗培南耐药显著相关,但非CG2病例在死亡病例中占比过高(相较于CG2病例)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAb) is 1 of the most problematic antimicrobial-resistant bacteria. We sought to elucidate the international epidemiology and clinical impact of CRAb. METHODS: In a prospective observational cohort study, 842 hospitalized patients with a clinical CRAb culture were enrolled at 46 hospitals in five global regions between 2017 and 2019. The primary outcome was all-cause mortality at 30 days from the index culture. The strains underwent whole-genome analysis. RESULTS: Of 842 cases, 536 (64%) represented infection. By 30 days, 128 (24%) of the infected patients died, ranging from 1 (6%) of 18 in Australia-Singapore to 54 (25%) of 216 in the United States and 24 (49%) of 49 in South-Central America, whereas 42 (14%) of non-infected patients died. Bacteremia was associated with a higher risk of death compared with other types of infection (40 [42%] of 96 vs 88 [20%] of 440). In a multivariable logistic regression analysis, bloodstream infection and higher age-adjusted Charlson comorbidity index were independently associated with 30-day mortality. Clonal group 2 (CG2) strains predominated except in South-Central America, ranging from 216 (59%) of 369 in the United States to 282 (97%) of 291 in China. Acquired carbapenemase genes were carried by 769 (91%) of the 842 isolates. CG2 strains were significantly associated with higher levels of meropenem resistance, yet non-CG2 cases were over-represented among the deaths compared with CG2 cases. CONCLUSIONS: CRAb infection types and clinical outcomes differed significantly across regions. Although CG2 strains remained predominant, non-CG2 strains were associated with higher mortality. Clinical Trials Registration. NCT03646227.
引用
- Wang M, Ge L, Chen L, et al. Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions. Clin Infect Dis. 2024. PMID: 37738153. doi:10.1093/cid/ciad556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。